Omeros Corporation (OMER) is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, coagulopathies and disorders of the central nervous system. Their most clinically advanced product candidates are derived from proprietary PharmacoSurgery platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures.
Maxim Group has initiated coverage of Omeros Corporation, giving it a "Buy" recommendation and a 12-month target price of $23.
Analyst Jason Kolbert writes,
"Omeros is an unusual combination of specialty pharmaceuticals and biotechnology drug discovery. On the specialty pharma side, we see great value in the ophthalmological surgery program. While we believe in the arthroscopic surgery platform, we are staying on the conservative side and not including positive results in our FCF or EPS models."